. Introduction {#s01}
==============

Despite the decrease in the incidence of gastric cancer over the past few decades, it remains the second most common cause of cancer-related death among carcinomas in the world, with 738,000 deaths globally, mainly in Latin America, Eastern Europe and Eastern Asia ([@b1]-[@b4]). In many countries, including China, gastric cancer patients are diagnosed at a relatively advanced stage ([@b5]). In addition, 30%−60% of gastric cancer patients were found to have peritoneal dissemination at the time of diagnosis and have a median survival time of only 3−6 months ([@b6]).

Despite the progress in surgery, chemotherapy and radiotherapy, the prognosis of gastric cancer is still unsatisfactory ([@b7]). Recently, the molecular targeting of genes, such as human epidermal growth factor receptor 2 (*Her2*), has been the focus of many gastric cancer investigations, and several molecular targeting agents have been approved for use in clinic practice due to their beneficial effects on the short-term survival of gastric cancer patients with or without peritoneal dissemination ([@b8],[@b9]). However, the effects of Trastuzumab on the subgroup of patients with peritoneal dissemination have been unclear.

In the clinical setting, the 7th version of the TNM Staging System of the American Joint Committee on Cancer (AJCC) is used to stage gastric cancer patients and predict their prognosis. However, other important clinicopathological features, including the gross type and patient age, among others, are not taken into consideration in this system. We and other investigators have found that gastric cancer patients may have a different prognosis even when they are classified in the same stage. Above all, a more reliable tool is needed to predict the prognosis of patients so better treatments can be administered. A nomogram is an efficient tool to quantify risks by combining all known prognostic factors using statistical software and has demonstrated practical use in the diagnosis of several diseases. There are already a few nomograms that have been developed to estimate the prognosis of gastric cancer, for example, the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram for gastric cancer, which is used to predict the 5-year and 9-year disease-specific survival (DSS) after an R0 resection without any other therapy, has been widely validated and proven to be accurate ([@b10]-[@b21]). We have observed that some patients with gastric cancer with peritoneal dissemination (GCPD) achieved a better prognosis after receiving palliative gastrectomy, chemotherapy or hyperthermic intraperitoneal chemotherapy (HIPEC). However, it is difficult to identify these patients clinically. In this study, we tried to develop a nomogram model to predict the prognosis of gastric cancer patients with peritoneal dissemination by months of survival, for the purpose of screening out appropriate patients for more aggressive treatment.

. Materials and methods {#s02}
=======================

. Ethics statement {#s02.01}
------------------

All the patients provided written informed consent for their information to be stored in the hospital database of the Sixth Affiliated Hospital of Sun Yat-sen University and the Sun Yat-sen University Cancer Center. We obtained separate consent for the use of this information for research. Study approval was obtained from the independent Ethics Committees of the Sixth Affiliated Hospital of Sun Yat-sen University and the Sun Yat-sen University Cancer Center. This study was performed in accordance with the ethical standards of the World Medical Association Declaration of Helsinki.

. Patient inclusion and exclusion criteria {#s02.02}
------------------------------------------

The inclusion criteria were as follows: 1) histologically proven adenocarcinoma of the stomach with synchronous peritoneal dissemination at the time of surgery or biopsy; and 2) no other synchronous or metachronous cancers. The exclusion criteria were as follows: 1) incomplete or important data censored; 2) patients with mental disorders or severe dysfunction of the liver and/or kidneys; or 3) no pathological diagnosis of peritoneal dissemination.

. Peritoneal seeding status {#s02.03}
---------------------------

We classified peritoneal seeding status according to the first English edition of the Japanese Classification of Gastric Carcinoma ([@b22]). The classification was as follows: P0, no peritoneal seeding; P1, disseminated metastasis to the region directly adjacent to the peritoneum of the stomach (above the transverse colon, including the greater omentum); P2, several scattered metastases to the distant peritoneum and ovarian metastasis only; and P3, numerous metastases to the distant peritoneum.

. Follow-up {#s02.04}
-----------

After treatment, the patients were monitored every month for the first year, every 3 months for the second year, and every 6 months thereafter, with regular follow-up assessments. We always followed up using telephone interviews, a follow-up letter, a short message platform and an email.

. End points {#s02.05}
------------

In our research, the end point is the overall survival of patients with peritoneal dissemination. We followed up all the patients until June 2017 or the death of patients.

. Statistical analysis {#s02.06}
----------------------

All data were analyzed using IBM SPSS Statistics (Version 20.0; IBM Corp., New York, USA) and R software (version 3.4.2; R Foundation for Statistical Computing, Vienna, Austria). The clinicopathological parameters between the development cohort and the validation cohort were analyzed using a Chi-square test or Fisher's exact test. Then, we performed a Kaplan-Meier analysis and Cox regression analysis to evaluate the independent prognostic factors for overall survival of the gastric cancer patients with peritoneal dissemination.

A nomogram was developed as a tool to predict the prognosis of gastric cancer patients with peritoneal dissemination by the months of survival. It graphically presents the patient prognosis. The nomogram and the calibration curve were displayed using the package of Regression Modeling Strategies in R. The predictive performance of this model was evaluated in the test group using the concordance index (C-index) ([@b11]). P\<0.05 was considered statistically significant.

. Results {#s03}
=========

. Patient characteristics {#s03.01}
-------------------------

From January 2000 to December 2014, a total of 746 patients with histologically diagnosed GCPD were included in the present study: 684 consecutive patients from Sun Yat-sen University Cancer Center comprised the development cohort, and the other 62 consecutive patients from the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China comprised the validation cohort. The flow chart is shown in *[Figure 1](#Figure1){ref-type="fig"}*. All cases of peritoneal dissemination were proven clinicopathologically at surgery. The clinicopathological factors for the development set and validation set are shown in *[Table 1](#Table1){ref-type="table"}*. Among the 684 patients from Sun Yat-sen University Cancer Center, 31 patients received gastrectomy +perioperative chemotherapy; 195 patient received gastrectomy + postoperative chemotherapy; 70 patients received gastrectomy only; 31 patients received bypass surgery + postoperative chemotherapy; 37 patients received bypass surgery only; another 226 patients received palliative chemotherapy only, and the remaining 94 patients did not receive any therapy. In addition, among the 62 patients from the Sixth Affiliated Hospital of Sun Yat-sen University, 3 patients received gastrectomy +perioperative chemotherapy; 45 patient received gastrectomy + postoperative chemotherapy; 3 patients received bypass surgery only; another 3 patients received palliative chemotherapy only; and the remaining 8 patients did not receive any therapy. Regarding hyperthermic intraperitoneal perfusion, 24 patients in the development group and 16 patients in the validation group accepted this treatment after surgery. None of the patients received targeted chemotherapy according to our records. Patient survival was measured from the diagnosis of peritoneal dissemination. The median follow-up time and median survival for all patients were 12.5 (range: 1−152) months and 11.5 \[95% confidence interval (95% CI): 10.4−12.6\] months, respectively.

. Univariate and multivariate analyses (Cox's regression) of gastric cancer patients in development set {#s03.02}
-------------------------------------------------------------------------------------------------------

Univariate analysis showed that tumor size, serum carcinoembryonic antigen (CEA) level, ascites grading, presence of extraperitoneal metastasis, seeding status and performance status were prognostic factors for these patients. We included these clinicopathological factors identified as prognostic factors in the univariate analysis (P\<0.05) for the Cox regression model. Multivariate analysis showed that serum CEA level, ascites grading, presence of extraperitoneal metastasis, seeding status and performance status were independent prognostic factors for gastric cancer patients with peritoneal dissemination in the development set. The results of the univariate and multivariate analyses are shown in*[Table 2](#Table2){ref-type="table"}*.

. Development and internal validation of nomogram model to predict prognosis of gastric cancer patients with peritoneal dissemination {#s03.03}
-------------------------------------------------------------------------------------------------------------------------------------

Along with the visualized tool provided by the nomogram, we then used the Cox regression model to predict the prognosis by months of survival of the gastric cancer patients with peritoneal dissemination. The nomogram model is shown in *[Figure 2](#Figure2){ref-type="fig"}*.

We performed an internal validation to validate this nomogram and found that the concordance index was 0.641, which closely corresponded to the actual survival. The internal calibration curves for half-, 1- and 2-year survival are shown in *[Figure 3](#Figure3){ref-type="fig"}*. As shown in *[Figure 3](#Figure3){ref-type="fig"}*, the black line represents the predicted values of the nomogram, while the gray line represents the actual values. The less discrepant they are, the more precise the predictive capability of the model is. For the internal calibration, the black lines fluctuated above and below the gray lines, to identify a reliable predictive capability of the nomogram.

. External validation of nomogram model of gastric cancer patients from the Sixth Affiliated Hospital of Sun Yat-sen University {#s03.04}
-------------------------------------------------------------------------------------------------------------------------------

We used an external validation set, consisting of 62 gastric cancer patients from the Sixth Affiliated Hospital of Sun Yat-sen University, to characterize the discrimination of the newly developed nomogram model. The C-index was 0.709, and the external calibration curves for half-, 1- and 2-year survival are shown in *[Figure 4](#Figure4){ref-type="fig"}*. As shown in *[Figure 4](#Figure4){ref-type="fig"}*, the goodness of fit indicated relatively satisfactory predictive values in the external validation, even though the predicted half-year survival and the predicted 2-year survival were not as fit as the predicted 1-year survival.

. Discussion {#s04}
============

Peritoneal dissemination is one of the most common forms of metastasis for gastric cancer. Palliative chemotherapy has been the main treatment administered to gastric cancer patients with peritoneal dissemination. In the past few decades, researchers have devoted efforts toward the development of new treatments for gastric cancer patients with peritoneal dissemination, including radiotherapy, chemotherapy, and molecular targeted drugs ([@b23]). Unfortunately, the results of clinical trials have been unsatisfactory, although some patients were reported to experience prolonged survival after they received intraperitoneal perfusion of chemotherapy or combination treatment with chemoradiotherapy ([@b24]). Clinically, it is important to predict the prognosis of gastric cancer patients with peritoneal dissemination to ensure that they receive the most optimal treatment.

Currently, the 7th Edition of the AJCC Staging System is used clinically to predict the survival of gastric cancer patients. However, this system places all the gastric cancer patients with peritoneal dissemination into stage IV. In a previous report, it was found that the patient age, tumor location, total number of lymph nodes retrieved, postoperative recurrence, adjuvant radio/chemotherapy, the Lauren classification, etc. were related to the prognosis of gastric cancer patients ([@b10]-[@b14],[@b16]-[@b18],[@b25]-[@b27]). In our present study, we identified serum CEA level, ascites grading, presence of extraperitoneal metastasis, seeding status, and performance status as independent prognostic risk factors for GCPD patients by a Cox regression model. In our research, all the patients were gastric cancer patients with synchronous peritoneal dissemination. The prognostic influence of some proven clinicopathological factors, Lauren type, lymph node metastasis, lymphovascular and perineural invasion might be inconsequential in the presence of distant metastasis. In our previous study, we found that palliative gastrectomy can prolong the survival of GCPD patients without extraperitoneal metastasis when combined with more than five cycles, and particularly more than eight cycles, of first-line chemotherapy ([@b28]-[@b37]). In another study, it was shown that preoperative or postoperative chemotherapy on the basis of S-1, alone or combined with other chemotherapeutic agents such as cisplatin (SP therapy), paclitaxel or oxaliplatin as first-line chemotherapy can prolong patient survival, with one patient still alive three years after chemotherapy ([@b38]-[@b40]).

In support of the practicality of our model, the C-indexs were 0.641 and 0.709 in the internal and external validation subsets. This finding means that the model was still not precise enough and needed to be optimized, which might be related to the following reasons. First, the treatment strategies in this group of patients were complex. As aforementioned, there were 6 treatment strategies in our data: 1) gastrectomy + perioperative chemotherapy; 2) gastrectomy + postoperative chemotherapy; 3) gastrectomy only; 4) bypass surgery + postoperative chemotherapy; 5) bypass surgery + postoperative chemotherapy; 6) palliative chemotherapy only; and 7) no therapy. In addition, some patients received HIPEC. Different treatments may affect the prognoses of the patients. Second, we only included the preoperative variables to construct the model to make it fit clinically. However, the effects of the treatments were disregarded in the model. Finally, this study had bias because it was a retrospective study; moreover, for the validation group, more patients from multiple centers will be needed for external validation to fully examine this model. However, the calibration was unsatisfactory, which we believe may be related to the different treatment strategies accepted in the validation group compared with those in the development group. The percentage of patients in the validation group who received chemotherapy was lower than that of the development group. This observation may account for the lower fitness of the predicted half-year survival and of the predicted 2-year survival. In addition, the number of patients in the validation group is too small, which also may have caused bias in the calibration curve. In conclusion, we have reasons to believe that the nomogram we constructed has prognostic potential accordingly.

We therefore believe that this model can be used to predict the prognosis of GCPD. Chemotherapy is currently the mainstay of treatment for GCPD patients. However, some of these patients were shown to have a better prognosis under comprehensive therapy that included surgery and other approaches. This model could be practical for suggesting the optimal clinical treatment for these patients. For example, for the patients predicted to have a better prognosis, aggressive treatments including surgery or HIPEC should be considered. For the patients predicted to have a poor prognosis, only palliative therapy should be administered. We are the first to identify possible risk factors for patients with peritoneal dissemination in a nomogram and believe that this model should permit individualized survival prediction and provide better treatment allocation than the existing systems. We believe that our nomogram may assist surgeons in selecting the appropriate treatment for gastric cancer patients with regard to the probability of a survival benefit.

As shown in *[Table 1](#Table1){ref-type="table"}*, there were several clinicopathological factors that differed significantly between the development group and the validation group, such as signet-ring cell carcinoma, peritoneal seeding, extraperitoneal metastasis, performance status, and palliative chemotherapy. Among them, peritoneal seeding, extraperitoneal metastasis and performance status were included in the nomogram model, which may demonstrate the validity of the model for two different groups of patients. However, the ratio of the palliative chemotherapy group may cause a deviation of the prediction from the model because different treatment strategies may cause survival differences. Another group of patients who had treatment strategies similarly proportional to those of the development group may be needed to validate the accuracy of the model.

There are some limitations associated with our study. First, although we constructed a robust nomogram model for prognostic prediction, more patients from multiple centers will be needed for external validation to fully examine this model. In addition, we removed some patients who had been lost to follow-up or discontinued follow-up for various reasons. Other patients were also removed because of missing data, such as tumor size, precise pathological staging and performance status. Second, the findings may not be generalizable to gastric cancer in Western countries.

. Conclusions {#s05}
=============

We have constructed a nomogram to estimate the survival of gastric cancer patients with peritoneal dissemination. The internal and external validations showed that this model can effectively predict the prognosis of gastric cancer patients with peritoneal dissemination. However, the number of subjects included in the external validation set was too small. More data are needed to validate and modify this model.
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###### 

Clinical pathological data of gastric cancer patients (N=746)

  Variables                      Development set (N=684)          Validation set (N=62)   P           
  ------------------------------ ------------------------- ------ ----------------------- ---- ------ ---------
  Age                                                                                                 0.121
  　≥65 years                    120                       17.5                           16   25.8   
  Sex                                                                                                 0.790
  　Male                         370                       54.1                           32   51.6   
  Tumor location                                                                                      0.146
  　Gastric cardia               195                       28.5                           25   40.3   
  　Middle                       220                       32.2                           16   25.8   
  　Antrum                       269                       39.3                           21   33.9   
  Tumor size                                                                                          0.188
  　\<5 cm                       202                       29.5                           13   21.0   
  CEA level                                                                                           0.884
  　\<5 μg/mL                    485                       70.9                           45   72.6   
  Pathological staging                                                                                0.131
  　Well                         12                        1.8                            3    4.8    
  　Moderate                     44                        6.4                            7    11.3   
  　Poor                         628                       91.8                           52   83.9   
  Signet ring cell carcinoma                                                                          \<0.001
  　Yes                          248                       36.3                           9    14.5   
  　No                           431                       63.0                           42   67.7   
  　Undefined                    5                         0.7                            11   17.7   
  Peritoneal seeding                                                                                  \<0.001
  　1                            136                       19.9                           27   43.5   
  　2                            211                       30.8                           9    14.5   
  　3                            337                       49.3                           26   41.9   
  Ascites grading\*                                                                                   0.448
  　0                            372                       54.4                           40   64.5   
  　1                            136                       19.9                           11   17.7   
  　2                            76                        11.1                           5    8.1    
  　3                            100                       14.6                           6    9.7    
  Extraperitoneal metastasis                                                                          0.008
  　Without                      438                       64.0                           50   80.6   
  Performance status\*\*                                                                              0.031
  　0                            137                       20.0                           10   16.1   
  　1                            367                       53.7                           25   40.3   
  　2                            148                       21.6                           21   33.9   
  　3                            32                        4.7                            6    9.7    
  Pathological T staging\*\*\*                                                                        0.154
  　T3                           114                       38.5                           24   50.0   
  　T4a/b                        182                       61.5                           24   50.0   
  Table 1 (*continued*)                                                                               

  Table 1 (*continued*)                                      
  ------------------------------ ----- ------ -- ---- ------ -------
  Pathological N staging\*\*\*                               0.382
  　N1                           7     2.4       0    0      
  　N2                           152   51.4      22   45.8   
  　N3a/b                        137   46.3      26   54.2   
  Palliative chemotherapy                                    0.030
  　Yes                          483   70.6      35   56.5   
  　No                           201   29.4      27   43.5   

###### 

Univariate and multivariate analysis of gastric cancer patients in development cohort (N=684)

  Variables                    Univariate analysis                         Multivariate analysis                            
  ---------------------------- --------------------- --------------------- ----------------------- -- ------- ------------- ---------
  Sex                                                                                                                       
  　Male                       370                   10.97 (9.33−12.60)    0.684                                            
  　Female                     314                   11.33 (9.65−13.01)                                                     
  Tumor location                                                                                                            
  　Upper                      195                   10.20 (8.44−11.96)    0.107                                            
  　Middle                     220                   11.27 (8.82−13.72)                                                     
  　Antrum                     269                   12.10 (10.33−13.87)                                                    
  Tumor size (cm)                                                                                                           
  　\<5                        202                   13.23 (10.68−15.78)   0.020                      1.203   0.984−1.471   0.072
  　≥5                         482                   10.17 (8.82−11.51)                                                     
  CEA level (μg/mL)                                                                                                         
  　\<5                        485                   12.43 (10.99−13.87)   0.002                      1.239   1.019−1.507   0.032
  　≥5                         199                   8.97 (7.29−10.65)                                                      
  Signet ring cell carcinoma                                                                                                
  　Yes                        248                   10.37 (9.02−11.71)    0.211                                            
  　No                         431                   12.43 (10.79−14.08)                                                    
  　Undefined                  5                     9.03 (5.34−12.72)                                                      
  Peritoneal seeding                                                                                                        
  　1                          136                   15.07 (11.09−19.05)   \<0.001                    1                     0.016
  　2                          211                   13.53 (11.38−15.68)                              1.107   0.853−1.435   0.446
  　3                          337                   8.57 (7.28−9.85)                                 1.410   1.093−1.819   0.008
  Ascites grading                                                                                                           
  　0                          372                   14.27 (12.39−16.14)   \<0.001                    1                     0.008
  　1                          136                   9.73 (7.63−11.83)                                1.169   0.918−1.489   0.204
  　2                          76                    6.73 (5.76−7.71)                                 1.421   1.050−1.921   0.023
  　3                          100                   8.10 (6.52−9.68)                                 1.591   1.182−2.141   0.002
  Extraperitoneal metastasis                                                                                                
  　Without                    438                   13.23 (11.42−15.04)   \<0.001                    1.506   1.246−1.819   \<0.001
  　With                       246                   8.17 (6.72−9.62)                                                       
  Performance status                                                                                                        
  　0                          137                   11.30 (8.90−13.70)    \<0.001                    1                     0.009
  　1                          367                   12.36 (10.77−13.96)                              0.875   0.693−1.104   0.261
  　2                          148                   9.30 (7.57−11.03)                                1.193   0.910−1.564   0.201
  　3                          32                    9.37 (9.96−12.24)                                0.557   0.983−2.465   0.059

[^1]: \*These authors contributed equally to this work.
